Psicofarma S.A. de C.V.

An EMIS Company Report EMIS is a Euromoney Institutional Investor plc company USD 9.95 Industry: Chemical Manufacturing Available in: English & Spanish Format: PDF Download Buy full report

What’s included?

This report extracts all available information about this company from EMIS' database of company information. The Table of Contents on the right indicates the categories of information that will be included in your report upon purchase.

Download a sample report

Company Tear Sheet (locked content will be provided in the purchased report)

Contact Information

Calzada De Tlalpan 4369, Col. Toriello Guerra
Mexico City; Federal District of Mexico City; Map
Postal Code: 14050

Tel: +52 558503

Company Description
Psicofarma was established in 1974. It is a pharmaceutical company focused on the development and manufacture of medicines for patients with psychiatric and neurological disorders. Its product portfolio includes medicines for several therapeutic groups such as antidepressants, anticonvulsants, anxiolytics, antiparkinsonian, antipsychotics and psychostimulants. It is part og Grupo Neolpharma.
NAICS Industry Classification
Basic Information
Key Executives
Ownership Details

You’re in good company

EMIS company reports are used extensively by the world’s biggest companies, financial institutions, professional service companies and universities to assess businesses in emerging markets.


company profiles

We have information on both public and private companies across 125 countries.



EMIS is the go-to information source on emerging market companies for the world’s most prestigious businesses.

Enterprise ACCESS

If you need regular and ongoing access to company information, you should consider a subscription to the full EMIS service.

EMIS company profiles are part of a larger information service where that combines company, industry and country data and analysis for over 125 emerging markets on a unique information platform.

Contact us to learn more about our business solutions.
Sign up to our newsletter

Make sure you’re not the last to know by getting the latest insights on emerging markets straight to your inbox.